Roche Acquires Nanopore Sequencing Firm Genia Technologies for up to $350M | GenomeWeb

NEW YORK (GenomeWeb) – Roche said today that it will acquire Genia Technologies for $125 million in cash and up to $225 million in additional payments tied to milestones. Once the deal closes, Genia will be integrated into the Roche Sequencing Unit.

Genia, based in Mountain View, Calif., has been developing a single-molecule sequencing-by-synthesis technology that uses nanopore-based electrical detection and employs a semiconductor integrated circuit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.